128 related articles for article (PubMed ID: 36683590)
1. First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept.
Velthuis K; Jessurun NT; Nguyen TDM; Scholl J; Jansen JRG; van Lint JA; Kosse LJ; Ten Klooster PM; Vonkeman HE
Expert Opin Drug Saf; 2023; 22(6):485-492. PubMed ID: 36683590
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals.
van Lint JA; Jessurun NT; Tas SW; van den Bemt BJF; Nurmohamed MT; van Doorn MBA; Spuls PI; van Tubergen AM; Ten Klooster PM; van Puijenbroek EP; Hoentjen F; Vonkeman HE
J Rheumatol; 2021 Sep; 48(9):1388-1394. PubMed ID: 33993115
[TBL] [Abstract][Full Text] [Related]
3. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
PLoS One; 2019; 14(5):e0216624. PubMed ID: 31067271
[TBL] [Abstract][Full Text] [Related]
4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
5. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Hirano T; Hara R; Katayama M; Onishi A; Nagai K; Son Y; Amuro H; Yamamoto K; Maeda Y; Murata K; Jinno S; Takeuchi T; Hirao M; Kumanogoh A; Yoshikawa H
Arthritis Res Ther; 2019 Apr; 21(1):91. PubMed ID: 30971306
[TBL] [Abstract][Full Text] [Related]
6. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
7. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
[TBL] [Abstract][Full Text] [Related]
8. Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice.
Leon L; Gomez A; Vadillo C; Pato E; Rodriguez-Rodriguez L; Jover JA; Abasolo L
Clin Exp Rheumatol; 2018; 36(1):29-35. PubMed ID: 28598787
[TBL] [Abstract][Full Text] [Related]
9. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
[TBL] [Abstract][Full Text] [Related]
10. Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study.
van Straalen JW; de Roock S; Giancane G; Consolaro A; Rygg M; Nordal EB; Rubio-Pérez N; Jelusic M; De Inocencio J; Vojinovic J; Wulffraat NM; Bruijning-Verhagen PCJ; Ruperto N; Swart JF;
Pediatr Rheumatol Online J; 2022 Nov; 20(1):96. PubMed ID: 36376976
[TBL] [Abstract][Full Text] [Related]
11. Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).
Soubrier M; Pereira B; Fan A; Frayssac T; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1986-1992. PubMed ID: 30168265
[TBL] [Abstract][Full Text] [Related]
12. Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.
García-Lagunar MH; Gutiérrez-Cívicos MR; García-Simón MS; Conesa-Zamora P; Jimenez-Santos E; Cano-Vivar P; García-Márquez A; Muñoz-García I; Viney AC
Ann Pharmacother; 2017 May; 51(5):388-393. PubMed ID: 27920336
[TBL] [Abstract][Full Text] [Related]
13. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Shiba H; Son Y; Amuro H; Onishi A; Akashi K; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
Arthritis Res Ther; 2020 Jun; 22(1):142. PubMed ID: 32539813
[TBL] [Abstract][Full Text] [Related]
14. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real-world finding.
Yu Z; Gao L; Zang Y; Cheng L; Gao W; Xu Y
Immun Inflamm Dis; 2024 Feb; 12(2):e1166. PubMed ID: 38415932
[TBL] [Abstract][Full Text] [Related]
16. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
17. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
18. Is drug discontinuation risk of adalimumab compared with etanercept affected by concomitant methotrexate dose in patients with rheumatoid arthritis?
Chen HH; Chen DY; Chen YM; Tang CH
Patient Prefer Adherence; 2016; 10():123-34. PubMed ID: 26917952
[TBL] [Abstract][Full Text] [Related]
19. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases.
Gosselt HR; van Lint JA; Kosse LJ; Spuls PI; Vonkeman HE; Tas SW; Hoentjen F; Nurmohamed MT; van den Bemt BJF; van Doorn MBA; Jessurun NT
Expert Opin Drug Saf; 2023; 22(6):501-507. PubMed ID: 36794307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
